WHITE PLAINS, NY, January 14, 2003 -- ORTHOMETRIX, INC. (OTCBB: OMRX) announced today the signing of an agreement with BonAlyse Ltd., a medical software company founded by professors and research scientists at the University of JyvŠskylŠ, Finland, to exclusively distribute BonAlyseÕs imaging software to Orthometrix peripheral Quantitative Computed Tomography (pQCT(tm)) and micro-CT customers in the U.S. and Canada. Over the past decade, pQCT has replaced Dual Energy Bone Absorptiometry (DEXA or DXA) as the technology of choice for pharmaceutical research laboratories specializing in bone disorders such as osteoporosis. Unlike DXA, pQCT allows true volumetric measurement of both bones and muscles, allowing not only faster assessment of new therapeutic agents but also their impact on the entire musculoskeletal system. BonAlyseÕs advanced medical software is used to analyze cross-sectional images acquired on pQCT and QCT systems, including assessment of bone density and bone geometry, muscle and fat (intramuscular and subcutaneous) cross-sectional area, and line analysis of distance and tissue thickness measurements.

Orthometrix, Inc. markets, sells and services several musculoskeletal product lines used in pharmaceutical research, diagnostic and monitoring of bone and muscle disorders, sports medicine, rehabilitative medicine, physical therapy and pain management. Our new Web address is www.orthometrix.net.

BonAlyse Ltd. develops and produces medical software for bone and soft tissue researchers and radiologists to carry out more comprehensive analyses for different anatomical sites for both human patients and animal research. BonAlyseÕs Web address is www.bonalyse.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this release are forward looking statements that involve risk and uncertainties, including, but not limited to, any potential impact on sales of the BonAlyse software to pharmaceutical research laboratories specializing in bone disorders such as osteoporosis, and other risks detailed in the documents periodically filed with the Securities and Exchange Commission, specifically the most recent reports on Forms 10-K and 10-Q. These risks and uncertainties could cause actual results to differ materially from those expected and/or contained in the forward-looking statements. Any forward-looking statement made in this release is made as of the date of this release and the Company assumes no obligation, subject to applicable law, to update such forward-looking statement.

###